


STEP 4

SEMAGLUTIDE 2.4 versus Placebo (FPO)



STEP 4 was a **68-week**, phase 3, randomized, placebo-controlled, double-blind, multicenter, multiple-dose withdrawal trial with a **20-week** run-in period and **48-week** on-dose maintenance period followed by a **7-week** off-treatment follow-up in **803 patients** with obesity or overweight and at least 1 comorbidity.

Select Eligibility Criteria



- BMI: ≥ 30.0 kg/m² or ≥ 27 kg/m² with at least 1 comorbidity
- HbA_{1c} <6.5% (no diabetes)
- Stable body weight for at least 90 days

Study Design




After a 20-week run-in period, 803 patients were randomized (**2:1**) to blinded maintenance treatment with SEMAGLUTIDE 2.4 mg subcutaneous injection or placebo.

Key Results at 68 Weeks

Primary efficacy end point: Body weight % change from randomization (week 20) to week 68 with SEMAGLUTIDE 2.4 mg vs placebo

Treatment policy estimand

Mean baseline body weight: 96.1 kg




Analysis at Week 68	ETD	95% CI	P-value
Semaglutide 2.4 mg vs placebo	-14.8	[-16.0; -13.5]	<.0001 ✓

Supportive secondary end point: Body weight % change from week 0 to week 78 with SEMAGLUTIDE 2.4 mg vs placebo

Observed mean

Mean baseline body weight at start of run-in (Week 0): 107.2kg



68*, estimated means. Error bars \pm standard error of the mean. Numbers shown in the lower panel are numbers of subjects contributing to the mean.

Analysis at Week 68	ETD	95% CI	P-value
SEMAGLUTIDE 2.4 mg vs placebo	-12.4	[-13.7; -11.0]	<.0001 ✓



Other confirmatory end points:

(change at 68 weeks)

WAIST CIRCUMFERENCE

SYSTOLIC BLOOD PRESSURE

SF-36 PHYSICAL FUNCTION SCALE SCORE

Safety



- The most common AEs with SEMAGLUTIDE 2.4 mg were gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation.
- Discontinuations due to AEs occurred at similar rates in the SEMAGLUTIDE 2.4 mg and placebo arms (1.5% vs 2.6%).

AE, adverse event; BMI, body mass index; ETD, estimated treatment difference; HbA_{1c}, glycosylated hemoglobin; OR, odds ratio; SF-36, Short Form 36.